[Federal Register Volume 75, Number 90 (Tuesday, May 11, 2010)]
[Notices]
[Pages 26258-26260]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-11173]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Erythroid Progenitor Cell Line for Hematological Disease Applications
Description of Invention: Plasmodium vivax (malaria) is a
significant health concern in many parts of Asia, Latin America, North
Africa, and the Middle East. There is a lack of continuous culture
systems for this pathogen. The subject technology is an erythroid
progenitor continuous cell line (termed CD36E) identified by erythroid
markers CD36, CD33, CD44, CD71, CD235, and globoside. These CD36E cells
are heterozygous for Fya and Fyb (Duffy antigen). Due to recent
evidence that Plasmodium vivax (P. vivax) can infect erythroid
progenitor cells (reference: YX Ru et al. and T Panichakul et al.),
these cells can be potentially used for culturing P. vivax and other
species of malaria. This in turn could aid development of malaria
related treatments and/or products. In addition, the cell line can also
be used for other hematological disease applications that involve red
blood cells or red blood cell precursors. The CD36E cells also produce
alpha, beta, and chi hemoglobin and therefore may be used for research
involving hemoglobin.
Applications:
Culture system for Plasmodium species (malaria)
Hematological diseases
Advantages: Immortalized erythroid progenitor cell line.
Development Status: In vitro data can be provided upon request.
Market:
Malaria
Anti-malaria drug screening
Hematological diseases
Hemoglobin
Inventors: Susan Wong, Neal S. Young, Ning Zhi (NHLBI).
Relevant Publications:
1. YX Ru et al. Invasion of erythroblasts by Pasmodium vivax: A new
mechanism contributing to malarial anemia. Ultrastruct Pathol. 2009
Oct;33(5):236-242. [PubMed: 19895296].
2. T Panichakul et al. Production of erythropoietic cells in vitro
for continuous culture of Plasmodium vivax. Int J Parasitol. 2007
Dec;37(14):1551-1557. [PubMed: 17610880].
Patent Status: HHS Reference No. E-151-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for biological materials licensing.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
[email protected].
Collaborative Research Opportunity: The National Heart Lung and
Blood Institute, Hematology Branch, is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize the CD36E cell line. Please
contact Cecilia Pazman, Ph.D., at [email protected] for more
information.
Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and
Diagnostic Applications
Description of Invention: Parvovirus B19 (B19V) is the only known
pathogenic human parvovirus. Infection by this viral pathogen can cause
transient aplastic crisis in individuals with high red cell turnover,
pure red cell aplasia in immunosuppressed patients, and hydrops fetalis
during
[[Page 26259]]
pregnancy. In children, B19V most commonly causes erythema infectiosum,
or fifth's disease. Infection can also cause arthropathy and
arthralgia. The virus is very erythrotropic, targeting human erythroid
(red blood) progenitors found in the blood, bone marrow, and fetal
liver. Currently, there are no approved vaccines or antiviral drugs for
the treatment or prevention of B19V infection.
The subject technology is a series of plasmid constructs with codon
optimized B19 viral capsid genes (VP1 and VP2) that can be expressed in
mammalian cells. Transfection of vectors encoding these optimized VP1
and VP2 genes into different mammalian cell lines, including 293, Cos7,
and Hela cells produce virus-like particles (VLPs). The vectors include
bicistronic plasmids expressing the VP1 and VP2 proteins at different
ratios to produce B19V VLPs with optimal antigenicity for vaccine
applications. This technology can also be used for diagnostic
applications and development of a viral packaging system for producing
infectious B19V virus.
Applications:
VLPs based vaccines for the prevention and/or treatment of
B19V infection
DNA based vaccines for the prevention and/or treatment of
B19V infection
B19V diagnostics
Viral packaging system
Advantages:
Codon optimized VP1 and VP2 genes for better expression in
mammalian cell lines
Expression of B19V VLPs from ``nonpermissive'' cell lines
Development Status: In vitro data can be provided upon request.
Market:
B19V vaccines (VLPs and DNA)
B19V diagnostics
Inventors: Ning Zhi, Sachiko Kajigaya, and Neal S. Young (NHLBI).
Patent Status: U.S. Provisional Application No. 61/337,983 filed 12
Feb 2010 (HHS Reference No. E-011-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
[email protected].
Collaborative Research Opportunity: The National Heart Lung and
Blood Institute, Hematology Branch, is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize the subject technology.
Please contact Cecilia Pazman, Ph.D., at [email protected] for more
information.
Optimized Expression of IL-12 Cytokine Family
Description of Invention: The IL-12 family of cytokines (IL-12, IL-
23, and IL-27) has an important role in inflammation and autoimmune
diseases. IL-12 is produced by macrophages and dendritic cells in
response to certain bacterial and parasitic infections and is a
powerful inducer of IFN-gamma production. IL-23 is proposed to
stimulate a subset of T cells to produce IL-17, which in turn induce
the production of proinflammatory cytokines that lead to a protective
response during infection. IL-27 appears to have duel functions as an
initiator of TH1-type (cellular immunity) immune responses and as an
attenuator of immune/inflammatory responses.
The present inventions provide methods for improved expression of
multimeric proteins by engineering different ratios of the subunit
expression units in a cell or upon expression from a multi-promoter
plasmid having different strength promoters. The inventors have
improved the levels and efficiency of expression of the IL-12 family of
cytokines, which includes IL-12, IL-23, and IL-27, by adjusting the
transcription and translation of the alpha and beta subunits that
comprise the heterodimeric proteins. Optimal ratios of expression for
the two (2) subunits were determined for IL-12, IL-23, and IL-27.
Applications:
Tumor treatment
Anti-viral therapy
Anti-inflammatory therapy
Advantages: Increased expression and stability of in vitro
expressed IL-12, IL-23 and IL-27 cytokines
Development Status: In vitro data and data in animal models can be
provided upon request
Market:
Infectious Diseases
Cancer
Inflammatory Diseases
Inventors: George N. Pavlakis and Barbara K. Felber (NCI)
Patent Status: International PCT Patent Application No. PCT/US09/
043481 filed 11 May 2009, which published as WO 2009/140206 on 19 Nov
2009 (HHS Reference No. E-192-2008/1-PCT-02)
Licensing Status: Available for licensing.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
[email protected].
Collaborative Research Opportunity: The Center for Cancer Research,
Human Retrovirus Section, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize delivery of cytokines of the IL-12
family in cancer and other indications. Please contact John D. Hewes,
Ph.D. at 301-435-3121 or [email protected] for more information.
Radiotracers for Imaging Cannabinoid Sub-Type 1 (CB1)
Receptor
Description of Invention: The present invention relates to novel
radiolabeled compounds for imaging cannabinoid sub-type 1
(CB1) receptors in brains of mammals, particularly humans,
using positron emission tomography (PET) or single photon emission
computed tomography (SPECT). These radioligands can be used in clinical
research, diagnostics, or drug discovery and development, in that, they
permit understanding of the role of CB1 receptors in
neuropsychiatric disorders such as Parkinson's disease, Huntington's
disease, Alzheimer's disease, multiple sclerosis, depression, mood
disorder, anxiety, schizophrenia, drug addiction, alcohol disorder,
obesity and anorexia.
Applications:
In vivo imaging of CB1 receptor in mammals,
particularly humans
Diagnostic imaging of CB1 receptors in subjects
having a neurological, neuropsychiatric, neurodegenerative or other
condition and treatment
Pharmaceutical composition
Diagnostic kits
Advantages: The principal radioligand under the claim is effective
for imaging CB1 receptors in vivo with PET.
Development Status: Primary radioligand has been evaluated in non-
human primates with PET.
Market: Radioligands may be useful for performing drug occupancy
studies of CB1 receptors, and for neuropsychiatric studies
and investigations with imaging techniques (e.g., PET or SPECT).
Inventors: Victor W. Pike (NIMH), Sean R. Donohue (NIMH), et al.
Relevant Publications:
1. SR Donohue, C Halldin, VW Pike. Synthesis and structure-activity
relationships (SARs) of 1,5-diarylpyrazole cannabinoid type-1
(CB1) receptor ligands for potential use in molecular
imaging. Bioorg Med Chem. 2006 Jun 1;14(11):3712-3720. [PubMed:
16466922].
2. SR Donohue, VW Pike, SJ Finnema, P Truong, J Andersson, B
Guly[aacute]s, C Halldin. Discovery and labeling of high affinity 3,4-
diarylpyrazolines as
[[Page 26260]]
candidate radioligands for in vivo imaging of cannabinoid subtype-1
(CB1) receptors. J Med Chem. 2008 Sep 25;51(18):5608-5616.
[PubMed: 18754613].
Licensing Status: Available for licensing.
Licensing Contact: Susan Ano, PhD; 301-435-5515; [email protected].
Dated: May 5, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-11173 Filed 5-10-10; 8:45 am]
BILLING CODE 4140-01-P